News
· 1dNovo to part ways with longtime CEO Lars Fruergaard Jørgensen, citing weight of market pressures
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with Novo Nordisk's board of directors,
Barchart on MSN1d
Is Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his ...
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...
When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...
1don MSN
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback